18 MONTH A1C AND WEIGHT OUTCOMES OF EXENATIDE THERAPY IN PATIENTS WITH TYPE-2 DIABETES IN A REAL-WORLD STUDY

被引：2
|
作者：
Brixner, D. [1 ]
McAdam-Marx, C. [1 ]
Ye, X. [1 ]
Misurski, D. [2 ]
Wintle, M. [3 ]
Fabunmi, R. [3 ]
机构：
[1] Univ Utah, Coll Pharm, Salt Lake City, UT 84112 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73550-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A97 / A97
页数：1
相关论文
共 50 条
  • [21] Real-world comparative effectiveness of exenatide once weekly and liraglutide in patients with type 2 diabetes mellitus
    Saunders, W.
    Nguyen, H. Hiep
    Kalsekar, I.
    DIABETOLOGIA, 2014, 57 : S335 - S336
  • [22] Real-World Comparative Effectiveness of Exenatide Once Weekly and Liraglutide in Patients with Type 2 Diabetes Mellitus
    Saunders, William
    Nguyen, Hiep
    Kalsekar, Iftekhar
    DIABETES, 2014, 63 : A310 - A310
  • [23] Effects of Dulaglutide on Renal Function, Glycemic Control, and Weight Outcomes in Indian Patients with Type 2 Diabetes: A Real-World Study
    Patange, Sonali A.
    DIABETES, 2019, 68
  • [24] Insulin Pump Therapy in Type 1 Diabetes-a Real-World Study of Mortality and Clinical Outcomes
    Haughton, Sophie
    Riley, David
    Arshad, Muhammad Fahad
    Azmi, Shazli
    Malik, Rayaz A.
    Alam, Uazman
    Iqbal, Ahmed
    DIABETES, 2024, 73
  • [25] Blood Pressure Outcomes after 6 Months of Exenatide Treatment in Patients with Type 2 Diabetes in a Real World Study
    Fabunmi, Rosalind
    Mcadam-Marx, Carrie
    Ye, Xiangyang
    Misurski, Derek
    Brixner, Diana I.
    DIABETES, 2009, 58 : A125 - A125
  • [26] REAL WORLD OUTCOMES IN TYPE 2 DIABETES: LOWER COST OF TREATING PATIENTS TO A1C<7% WITH LIRAGLUTIDE VERSUS EXENATIDE
    Dekoven, M.
    Lee, W. C.
    Bouchard, J. R.
    Massoudi, M.
    Langer, J.
    VALUE IN HEALTH, 2013, 16 (07) : A438 - A438
  • [27] Glycaemic and weight-loss outcomes of graded doses of canagliflozin in type 2 diabetes - a real-world study
    Dutta, Deep
    Sharma, Meha
    Dhall, Anil
    Aggarwal, Sameer
    Khandelwal, Deepak
    CLINICAL DIABETOLOGY, 2020, 9 (06): : 442 - 453
  • [28] Real-World Adherence in Patients Aged=65 years with Type 2 Diabetes Mellitus for Exenatide QW, Liraglutide QD, and Exenatide BID
    Dufour, Robert
    Nguyen, Hiep
    Tarr, Amanda
    Bullano, Michael
    DIABETES, 2015, 64 : A294 - A295
  • [29] Treatment outcomes of graded dose of empagliflozin in type-2 diabetes: A real world study
    Dutta, Deep
    Sharma, Meha
    Aggarwal, Sameer
    Agarwal, Anshita
    Dhall, Anil
    ANNALS OF AFRICAN MEDICINE, 2022, 21 (01) : 26 - 33
  • [30] Real-World 1-Year HbA1c and Weight Outcomes in Patients Treated with Exenatide Once Weekly or Liraglutide Once Daily
    Mcadam-Marx, Carrie
    Nguyen, Hiep
    Schauerhamer, Marisa
    Ye, Xiang-Yang
    Singhal, Mukul
    Cobden, David
    DIABETES, 2015, 64 : A296 - A296
12345